<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Cetuximab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Cetuximab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Cetuximab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Cetuximab</b> is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name <b>Erbitux</b> in the U.S. and Canada by the drug company Eli Lilly and Co. and outside those countries by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution.</p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Cetuximab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Cetuximab.png" tppabs="https://ptable.com/wiki/compounds/I/m/Cetuximab.png" data-file-width="1020" data-file-height="623" data-file-type="bitmap" height="134" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Chimeric (mouse/human)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>EGF receptor</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Erbitux</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/cetuximab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/cetuximab.html'" tppabs="https://www.drugs.com/monograph/cetuximab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Cetuximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Cetuximab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Cetuximab" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Cetuximab&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Cetuximab&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=Cetuximab&SearchType=BasicSearch" class="external text external">Cetuximab</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>intravenous</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L01XC06<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L01XC06  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L01XC06'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L01XC06" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">CA</abbr></small>:<span> </span> ℞-only<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>114 hrs</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=205923-56-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=205923-56-4'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=205923-56-4" class="external text external">205923-56-4</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00002'" tppabs="https://www.drugbank.ca/drugs/DB00002" class="external text external">DB00002</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=PQX0D8J21J  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=PQX0D8J21J'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=PQX0D8J21J" class="external text external">PQX0D8J21J</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D03455  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D03455'" tppabs="https://www.kegg.jp/entry/D03455" class="external text external">D03455</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201577  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201577'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201577" class="external text external">ChEMBL1201577</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID0040830  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID0040830'" tppabs="https://comptox.epa.gov/dashboard/DTXSID0040830" class="external text external">DTXSID0040830</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6484</sub><span>H</span><sub>10042</sub><span>N</span><sub>1732</sub><span>O</span><sub>2023</sub><span>S</span><sub>36</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">145<span style="margin-left:.25em;">781</span>.92</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=460026782&page2=Cetuximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=460026782&page2=Cetuximab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=460026782&page2=Cetuximab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>In July 2009, the FDA approved cetuximab (Erbitux) for treatment of colon cancer with wild-type KRAS, since it had little or no effect in colorectal tumors harboring a KRAS mutation (this also applied to the EGFR antibody panitumumab).<span class="mw-ref" id="cite_ref-urlCetuximab_(Erbitux)_and_Panitumumab_(Vectibix)_1-0"><a href="#cite_note-urlCetuximab_(Erbitux)_and_Panitumumab_(Vectibix)-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> This was the first genetic test to guide treatment of cancer.<span class="mw-ref" id="cite_ref-Messersmith_Ahnen_2008_2-0"><a href="#cite_note-Messersmith_Ahnen_2008-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> In July 2012, the FDA approved a real time PCR companion diagnostic test for KRAS, the therascreen KRAS test.<span class="mw-ref" id="cite_ref-urltherascreen®_KRAS_RGQ_PCR_Kit_-_P110030_3-0"><a href="#cite_note-urltherascreen®_KRAS_RGQ_PCR_Kit_-_P110030-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<p>Cetuximab is approved for <span class="new">K-RAS</span> wild-type metastatic colorectal cancer in the US &amp; Canada (Eli Lilly). In Europe and the rest of the world (Merck KGaA), cetuximab is approved for RAS wild-type metastatic colorectal cancer.</p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    

<p>A diagnostic immunohistochemistry assay (EGFR pharmDx) can be used to detect EGFR expression in the tumor material. Approximately 75% of patients with metastatic colorectal cancer have an EGFR-expressing tumor and are therefore considered eligible for treatment with cetuximab or panitumumab, according to FDA guidelines. Unfortunately, there is evidence that immunohistochemical EGFR receptor testing does not predict response to either cetuximab or panitumumab, so that this has been called a "misleading biomarker" that has nevertheless caused insurers and even health systems to deny payment for EGFR antibody treatment for patients who lack a positive tumor EGFR histochemical test.<span class="mw-ref" id="cite_ref-Messersmith_Ahnen_2008_2-1"><a href="#cite_note-Messersmith_Ahnen_2008-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Head_and_neck_cancer">Head and neck cancer</h3></summary>
    

<p>Cetuximab was approved by the FDA in March 2006 for use in combination with radiation therapy for treating squamous cell carcinoma of the head and neck (SCCHN) or as a single agent in patients who have had prior platinum-based therapy.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>One of the more serious side effects of cetuximab therapy is the incidence of acne-like rash.  This rash rarely leads to dose reductions or termination of therapy. It is generally reversible.<span class="mw-ref" id="cite_ref-pmid19925924_5-0"><a href="#cite_note-pmid19925924-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>

<p>Further severe infusion reactions include but are not limited to: fevers, chills, rigors, urticaria, itchiness, rash, hypotension, nausea, vomiting, headache, shortness of breath, wheezing, angioedema, dizziness, anaphylaxis, and cardiac arrest.  Therefore, pretreatment with <a href="Diphenhydramine.htm" tppabs="https://ptable.com/wiki/compounds/A/Diphenhydramine" title="Diphenhydramine">diphenhydramine</a> (30 to 60) min before administration is standard of care.  Other common side effects include photosensitivity, hypomagnesemia due to magnesium wasting, and less commonly pulmonary and cardiac toxicity.
<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Alpha-gal_allergy">Alpha-gal allergy</h3></summary>
    
<p>Certain geographic regions have a high rate of anaphylactic reactions to cetuximab upon the first exposure to the medication. This is unusual because exposure to the allergen must occur before the development of an allergy. Fewer than 1% of people in the northeast United States reacted, while greater than 20% in the southeast did.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-Chi2008_8-0"><a href="#cite_note-Chi2008-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> The alpha-gal allergy is believed to result from tick bites. Lone star ticks are native to the regions of the US where reactions occurred and were found to be the vector. Cetuximab is produced in the mouse myeloma cell line SP2/0, and contains the alpha-gal oligosaccharide on the Fab portion of the heavy chain.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Cetuximab is a chimeric (mouse/human) monoclonal antibody which binds to and inhibits EGFR.<span class="mw-ref" id="cite_ref-Chi2008_8-1"><a href="#cite_note-Chi2008-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="KRAS_Testing">KRAS Testing</h2></summary>
    

<p>The KRAS gene encodes a small G protein on the EGFR pathway. Cetuximab and other EGFR inhibitors only work on tumors in which KRAS is not mutated.<span class="mw-ref" id="cite_ref-pmid19339720_9-0"><a href="#cite_note-pmid19339720-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-pmid22446022_10-0"><a href="#cite_note-pmid22446022-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-pmid22446022_10-1"><a href="#cite_note-pmid22446022-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>KRAS mutational analysis is commercially available from a number of laboratories.</p>

<p>In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumumab (Vectibix) and cetuximab (Erbitux)) indicated for treatment of metastatic colorectal cancer to include information about KRAS mutations.<span class="mw-ref" id="cite_ref-urlCetuximab_(Erbitux)_and_Panitumumab_(Vectibix)_1-1"><a href="#cite_note-urlCetuximab_(Erbitux)_and_Panitumumab_(Vectibix)-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>

<p>Studies have indicated that detection of KRAS gene mutations helps physicians identify patients that are unlikely to respond to treatment with targeted EGFR inhibitors, including cetuximab and panitumumab. Accordingly, genetic testing to confirm the absence of KRAS mutations (and so the presence of the KRAS wild-type gene), is now clinically routine before the start of treatment with EGFR inhibitors. mCRC patients with wild-type KRAS tumors have been shown to benefit from a response rate of over 60% and a decreased risk for progression of over 40% when treated with Erbitux as 1st-line therapy.  Around 65% of mCRC patients have the KRAS wild-type gene.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    

<p>Michael Sela, Ester Hurwitz  and co-workers published observations on EGFR inhibition in 1988.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span>  Yeda Research, on behalf of the Weizmann Institute of Science in Israel,<span class="mw-ref" id="cite_ref-urlwww.yedarnd.com_12-0"><a href="#cite_note-urlwww.yedarnd.com-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> challenged the Aventis-owned patent,<span class="mw-ref" id="cite_ref-Groombridge_Gearing_13-0"><a href="#cite_note-Groombridge_Gearing-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> licensed by Imclone, for the use of anti-epidermal growth factor receptor antibodies in combination with chemotherapy, to slow the growth of certain tumors which was filed in 1989 by Rhone-Poulenc-Rorer.<span class="mw-ref" id="cite_ref-US6217866_14-0"><a href="#cite_note-US6217866-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> The court ruled that Yeda is sole owner of the patent in the U.S., while Yeda and Sanofi-Aventis co-own the patent's foreign counterparts.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span><span class="mw-ref" id="cite_ref-USA_17-0"><a href="#cite_note-USA-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Manufacture">Manufacture</h3></summary>
    
<ul><li>Eli Lilly and Company is responsible for the manufacture and supply of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the U.S. and Canada.</li>
<li>Merck KGaA manufactures Erbitux for supply in its territory (outside the U.S. and Canada) as well as for Japan.<span class="mw-ref" id="cite_ref-investor.lilly.com_18-0"><a href="#cite_note-investor.lilly.com-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Distribution">Distribution</h3></summary>
    
<ul><li>Erbitux is marketed in the U.S. and Canada by Eli Lilly.</li>
<li>Outside the U.S. and Canada, Erbitux is commercialized by Merck KGaA. Eli Lilly receives royalties from Merck KGaA.</li>
<li>A separate agreement grants co-exclusive rights among Merck, Bristol-Myers Squibb and Eli Lilly in Japan and expires in 2032.<span class="mw-ref" id="cite_ref-investor.lilly.com_18-1"><a href="#cite_note-investor.lilly.com-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></li></ul>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Sales">Sales</h3></summary>
    

<p>Cetuximab is given by intravenous therapy and costs up to $30,000 for eight weeks of treatment per patient.<span class="mw-ref" id="cite_ref-Schrag_19-0"><a href="#cite_note-Schrag-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>

<p>Merck KGaA had 887 million euros ($1.15 billion) in Erbitux sales in 2012, from head and neck as well as bowel cancer, while Bristol-Myers Squibb generated $702 million in sales from the drug.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Erbitux was the eighth best-selling cancer drug of 2013, with sales of $1.87 billion.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>Erbitux had 2013 worldwide sales of US$1.9 billion making it a lucrative target for biosimilars developers. Additionally the patent protection for Erbitux in Europe expired in June 2014, and in the U.S. and in Japan the protection will expire in 2016.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> However biosimilars of Erbitux are not expected until 2018.<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p>

<p>As of 2014 biosimilars of cetuximab were in development by several companies.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Insider_trading">Insider trading</h3></summary>
    

<p>Cetuximab failed to get FDA approval in 2001, which caused the stock price of the developer ImClone to drop dramatically. Prior to the announcement, several executives sold stock, and the SEC launched an investigation into insider trading. This resulted in a widely publicized criminal case, which resulted in prison terms for media celebrity Martha Stewart, ImClone chief executive officer Samuel D. Waksal and Stewart's broker at Merrill Lynch, Peter Bacanovic.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>The efficacy of cetuximab was explored in a clinical trial of advanced gastric cancer published in 2013; cetuximab showed no survival benefit.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>

<p>A 2020 phase 3 multicentre randomized controlled trial headed by University College London showed that adding cetuximab to perioperative chemotherapy worsened survival for colorectal cancer patients with operable liver metastases. With over 5 years of follow-up, median overall survival (OS) dropped from 81 months for patients treated with chemotherapy alone before and after liver resection, to 55.4 months for those that also received cetuximab.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-urlCetuximab_(Erbitux)_and_Panitumumab_(Vectibix)-1"> <span id="mw-reference-text-cite_note-urlCetuximab_(Erbitux)_and_Panitumumab_(Vectibix)-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm172905.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm172905.htm'" tppabs="https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm172905.htm" class="external text external">"Class Labeling Changes to anti-EGFR monoclonal antibodies, cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations"</a>. U.S. Food and Drug Administration. 2010-01-11.</cite></span></li><li id="cite_note-Messersmith_Ahnen_2008-2"> <span id="mw-reference-text-cite_note-Messersmith_Ahnen_2008-2" class="mw-reference-text"><cite id="CITEREFMessersmithAhnen2008" class="citation journal cs1">Messersmith WA, Ahnen DJ (October 2008). "Targeting EGFR in colorectal cancer". <i>N. Engl. J. Med</i>. <b>359</b> (17): 1834–36. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMe0806778  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMe0806778'" tppabs="https://doi.org/10.1056%2FNEJMe0806778" class="external text external">10.1056/NEJMe0806778</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18946069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18946069'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18946069" class="external text external">18946069</a>.</cite></span></li><li id="cite_note-urltherascreen®_KRAS_RGQ_PCR_Kit_-_P110030-3"> <span id="mw-reference-text-cite_note-urltherascreen®_KRAS_RGQ_PCR_Kit_-_P110030-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm312055.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm312055.htm'" tppabs="https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm312055.htm" class="external text external">"Therascreen KRAS RGQ PCR Kit – P110030"</a>. <i>Device Approvals and Clearances</i>. U.S. Food and Drug Administration. 2012-07-06.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20101221093149/http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20101221093149/http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604#'" tppabs="https://web.archive.org/web/20101221093149/http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604#" class="external text external">"Cetuximab Beneficial in Head and Neck Cancer"</a>. Cancer.gov National Cancer Institute. Archived from <a href="javascript:if(confirm('http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604'" tppabs="http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604" class="external text external">the original</a> on 2010-12-21<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-04-13</span></span>.</cite></span></li><li id="cite_note-pmid19925924-5"> <span id="mw-reference-text-cite_note-pmid19925924-5" class="mw-reference-text"><cite id="CITEREFNguyenHoangLaquerKelly2009" class="citation journal cs1">Nguyen A, Hoang V, Laquer V, Kelly KM (December 2009). <a href="javascript:if(confirm('https://escholarship.org/content/qt5p17d7d9/qt5p17d7d9.pdf?t=piyl0b  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://escholarship.org/content/qt5p17d7d9/qt5p17d7d9.pdf?t=piyl0b'" tppabs="https://escholarship.org/content/qt5p17d7d9/qt5p17d7d9.pdf?t=piyl0b" class="external text external">"Angiogenesis in cutaneous disease: part I"</a> <span class="cs1-format">(PDF)</span>. <i>J. Am. Acad. Dermatol</i>. <b>61</b> (6): 921–42, quiz 943–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2009.05.052  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2009.05.052'" tppabs="https://doi.org/10.1016%2Fj.jaad.2009.05.052" class="external text external">10.1016/j.jaad.2009.05.052</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19925924  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19925924'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19925924" class="external text external">19925924</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text">8. Micromedex Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically
</span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFBergPlatts-MillsCommins2013" class="citation journal cs1">Berg, E. A.; Platts-Mills, T. A.; Commins, S. P. (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964477  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964477'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964477" class="external text external">"Drug allergens and food—the cetuximab and galactose-α-1,3-galactose story"</a>. <i>Annals of Allergy, Asthma &amp; Immunology</i>. <b>112</b> (2): 97–101. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.anai.2013.11.014  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.anai.2013.11.014'" tppabs="https://doi.org/10.1016%2Fj.anai.2013.11.014" class="external text external">10.1016/j.anai.2013.11.014</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964477  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964477'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964477" class="external text external">3964477</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24468247  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24468247'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24468247" class="external text external">24468247</a>.</cite></span></li><li id="cite_note-Chi2008-8"> <span id="mw-reference-text-cite_note-Chi2008-8" class="mw-reference-text"><cite id="CITEREFChungMirakhurChanLe2008" class="citation journal cs1">Chung, Christine H.; Mirakhur, Beloo; Chan, Emily; Le, Quynh-Thu; Berlin, Jordan; Morse, Michael; Murphy, Barbara A.; Satinover, Shama M.; Hosen, Jacob; Mauro, David; Slebos, Robbert J.; Zhou, Qinwei; Gold, Diane; Hatley, Tina; Hicklin, Daniel J.; Platts-Mills, Thomas A.E. (13 March 2008). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361129'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361129" class="external text external">"Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose"</a>. <i>The New England Journal of Medicine</i>. <b>358</b> (11): 1109–17. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa074943  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa074943'" tppabs="https://doi.org/10.1056%2FNEJMoa074943" class="external text external">10.1056/NEJMoa074943</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-4793  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-4793'" tppabs="https://www.worldcat.org/issn/0028-4793" class="external text external">0028-4793</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361129  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361129'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361129" class="external text external">2361129</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18337601  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18337601'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18337601" class="external text external">18337601</a>.</cite></span></li><li id="cite_note-pmid19339720-9"> <span id="mw-reference-text-cite_note-pmid19339720-9" class="mw-reference-text"><cite id="CITEREFVan_CutsemKöhneHitreZaluski2009" class="citation journal cs1">Van Cutsem E,  et al. (April 2009). "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer". <i>N. Engl. J. Med</i>. <b>360</b> (14): 1408–17. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa0805019  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa0805019'" tppabs="https://doi.org/10.1056%2FNEJMoa0805019" class="external text external">10.1056/NEJMoa0805019</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19339720  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19339720'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19339720" class="external text external">19339720</a>.</cite></span></li><li id="cite_note-pmid22446022-10"> <span id="mw-reference-text-cite_note-pmid22446022-10" class="mw-reference-text"><cite id="CITEREFBokemeyerVan_CutsemRougierCiardiello2012" class="citation journal cs1">Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne CH (July 2012). "Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials". <i>Eur. J. Cancer</i>. <b>48</b> (10): 1466–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.ejca.2012.02.057  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.ejca.2012.02.057'" tppabs="https://doi.org/10.1016%2Fj.ejca.2012.02.057" class="external text external">10.1016/j.ejca.2012.02.057</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22446022  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22446022'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22446022" class="external text external">22446022</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFAboud-PirakHurwitzPirakBellot1988" class="citation journal cs1">Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M (1988-12-21). "Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice". <i>J. Natl. Cancer Inst</i>. <b>80</b> (20): 1605–11. doi:<a href="javascript:if(confirm('https://doi.org/10.1093%2Fjnci%2F80.20.1605  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Fjnci%2F80.20.1605'" tppabs="https://doi.org/10.1093%2Fjnci%2F80.20.1605" class="external text external">10.1093/jnci/80.20.1605</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3193478  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3193478'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3193478" class="external text external">3193478</a>.</cite></span></li><li id="cite_note-urlwww.yedarnd.com-12"> <span id="mw-reference-text-cite_note-urlwww.yedarnd.com-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20161204093338/http://www.yedarnd.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20161204093338/http://www.yedarnd.com/'" tppabs="https://web.archive.org/web/20161204093338/http://www.yedarnd.com/" class="external text external">"Yeda Research and Development Company Ltd"</a>. Archived from <a href="javascript:if(confirm('http://www.yedarnd.com/+  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.yedarnd.com/+'" tppabs="http://www.yedarnd.com/+" class="external text external">the original</a> on 2016-12-04<span class="reference-accessdate">. Retrieved <span class="nowrap">2013-01-05</span></span>. <q>Technology Transfer Company of the Weizmann Institute of Science</q></cite></span></li><li id="cite_note-Groombridge_Gearing-13"> <span id="mw-reference-text-cite_note-Groombridge_Gearing-13" class="mw-reference-text"><cite id="CITEREFGroombridgeGearing2008" class="citation journal cs1">Groombridge N, Gearing BP (February 2008). <a href="javascript:if(confirm('https://web.archive.org/web/20090903012733/http://www.yedarnd.com/images/pics/UserImages/Practical_Lessons%20from%20a%20Made%20for%20TV%20Patent%20Litigation.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090903012733/http://www.yedarnd.com/images/pics/UserImages/Practical_Lessons%20from%20a%20Made%20for%20TV%20Patent%20Litigation.pdf'" tppabs="https://web.archive.org/web/20090903012733/http://www.yedarnd.com/images/pics/UserImages/Practical_Lessons%20from%20a%20Made%20for%20TV%20Patent%20Litigation.pdf" class="external text external">"Practical lessons from a "made for TV" patent litigation: The trial of Yeda Research &amp; Development Co. Ltd. v. ImClone Systems Inc. and Aventis Pharmaceuticals Inc"</a> <span class="cs1-format">(PDF)</span>. <i>The Federal Lawyer</i>: 51–55. Archived from <a href="javascript:if(confirm('http://www.yedarnd.com/images/pics/UserImages/Practical_Lessons%20from%20a%20Made%20for%20TV%20Patent%20Litigation.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.yedarnd.com/images/pics/UserImages/Practical_Lessons%20from%20a%20Made%20for%20TV%20Patent%20Litigation.pdf'" tppabs="http://www.yedarnd.com/images/pics/UserImages/Practical_Lessons%20from%20a%20Made%20for%20TV%20Patent%20Litigation.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2009-09-03.</cite></span></li><li id="cite_note-US6217866-14"> <span id="mw-reference-text-cite_note-US6217866-14" class="mw-reference-text"><span class="citation patent" id="CITEREFSela_M,_Pirak_E,_Hurwitz_E2020"><a href="javascript:if(confirm('https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US6217866  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US6217866'" tppabs="https://worldwide.espacenet.com/textdoc?DB=EPODOC&IDX=US6217866" class="external text external">US<span> </span>patent 6217866</a>,<span> </span>Sela M, Pirak E, Hurwitz E,<span> </span>"Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same",<span> </span>published 2001-04-17,<span> </span> assigned to Yeda Research &amp; Development</span></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20110927101421/http://www.nysd.uscourts.gov/rulings/03CV08484_opinion_091806.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110927101421/http://www.nysd.uscourts.gov/rulings/03CV08484_opinion_091806.pdf'" tppabs="https://web.archive.org/web/20110927101421/http://www.nysd.uscourts.gov/rulings/03CV08484_opinion_091806.pdf" class="external text external">"Court ruling on Yeda vs Aventis/Imclone case"</a> <span class="cs1-format">(PDF)</span>. Archived from <a href="javascript:if(confirm('http://www.nysd.uscourts.gov/rulings/03CV08484_opinion_091806.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nysd.uscourts.gov/rulings/03CV08484_opinion_091806.pdf'" tppabs="http://www.nysd.uscourts.gov/rulings/03CV08484_opinion_091806.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2011-09-27<span class="reference-accessdate">. Retrieved <span class="nowrap">2012-05-25</span></span>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20151120002423/http://www.legalmetric.com/cases/patent/nysd/nysd_103cv08484.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20151120002423/http://www.legalmetric.com/cases/patent/nysd/nysd_103cv08484.html'" tppabs="https://web.archive.org/web/20151120002423/http://www.legalmetric.com/cases/patent/nysd/nysd_103cv08484.html" class="external text external">"Archived copy"</a>. Archived from <a href="javascript:if(confirm('http://www.legalmetric.com/cases/patent/nysd/nysd_103cv08484.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.legalmetric.com/cases/patent/nysd/nysd_103cv08484.html'" tppabs="http://www.legalmetric.com/cases/patent/nysd/nysd_103cv08484.html" class="external text external">the original</a> on 2015-11-20<span class="reference-accessdate">. Retrieved <span class="nowrap">2015-08-30</span></span>.</cite><span class="cs1-maint citation-comment">CS1 maint: archived copy as title (link)</span></span></li><li id="cite_note-USA-17"> <span id="mw-reference-text-cite_note-USA-17" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.usatoday.com/money/industries/health/drugs/2006-09-14-imclone-usat_x.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.usatoday.com/money/industries/health/drugs/2006-09-14-imclone-usat_x.htm'" tppabs="https://www.usatoday.com/money/industries/health/drugs/2006-09-14-imclone-usat_x.htm" class="external text external">"ImClone goes up against patent dispute"</a>. USA Today. 2006-09-14.</cite></span></li><li id="cite_note-investor.lilly.com-18"> <span id="mw-reference-text-cite_note-investor.lilly.com-18" class="mw-reference-text"><a href="javascript:if(confirm('https://investor.lilly.com/financials.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://investor.lilly.com/financials.cfm'" tppabs="https://investor.lilly.com/financials.cfm" class="external text external">Eli Lilly and Company Form 10-K Annual Report 2013</a></span></li><li id="cite_note-Schrag-19"> <span id="mw-reference-text-cite_note-Schrag-19" class="mw-reference-text"><cite id="CITEREFSchrag2004" class="citation journal cs1">Schrag D (July 2004). "The price tag on progress – chemotherapy for colorectal cancer". <i>N. Engl. J. Med</i>. <b>351</b> (4): 317–19. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMp048143  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMp048143'" tppabs="https://doi.org/10.1056%2FNEJMp048143" class="external text external">10.1056/NEJMp048143</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15269308  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15269308'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15269308" class="external text external">15269308</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><a href="javascript:if(confirm('http://in.reuters.com/article/2013/06/01/us-erbitux-avastin-idINBRE95006O20130601?goback=.gde_1008637_member_245962179  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://in.reuters.com/article/2013/06/01/us-erbitux-avastin-idINBRE95006O20130601?goback=.gde_1008637_member_245962179'" tppabs="http://in.reuters.com/article/2013/06/01/us-erbitux-avastin-idINBRE95006O20130601?goback=.gde_1008637_member_245962179" class="external text external">Merck KGaA's Erbitux beats Avastin in bowel cancer trial, Reuters, Jun 1 2013</a></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><a href="javascript:if(confirm('http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs-2013  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs-2013'" tppabs="http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs-2013" class="external text external">Top 10 best-selling cancer drugs of 2013; May 29, 2014</a></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><a href="javascript:if(confirm('http://investor.bms.com/investors/financial-information/annual-reports/default.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://investor.bms.com/investors/financial-information/annual-reports/default.aspx'" tppabs="http://investor.bms.com/investors/financial-information/annual-reports/default.aspx" class="external text external">Bristol-Myers Squibb Company 2013 Form 10-K</a></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><a href="javascript:if(confirm('http://www.merckgroup.com/en/investors/merck_serono_day.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.merckgroup.com/en/investors/merck_serono_day.html'" tppabs="http://www.merckgroup.com/en/investors/merck_serono_day.html" class="external text external">Merck Serono Investor &amp; Analyst Day 2014 – Belen Garijo’s presentation – Slide 41. 18 Sept 2014</a></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><a href="javascript:if(confirm('http://www.gabionline.net/Biosimilars/General/Biosimilars-of-cetuximab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gabionline.net/Biosimilars/General/Biosimilars-of-cetuximab'" tppabs="http://www.gabionline.net/Biosimilars/General/Biosimilars-of-cetuximab" class="external text external">Generics and Biosimilars Initiative (GaBI) – Biosimilars of cetuximab – 14/08/2014</a></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><a href="javascript:if(confirm('http://www.business-standard.com/article/companies/torrent-pharma-reliance-life-sign-licensing-agreement-for-biosimilars-114122500631_1.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.business-standard.com/article/companies/torrent-pharma-reliance-life-sign-licensing-agreement-for-biosimilars-114122500631_1.html'" tppabs="http://www.business-standard.com/article/companies/torrent-pharma-reliance-life-sign-licensing-agreement-for-biosimilars-114122500631_1.html" class="external text external">Torrent Pharma, Reliance Life sign licensing agreement for biosimilars</a></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFLi_K,_Li_J2016" class="citation journal cs1">Li K, Li J (2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736909  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736909'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736909" class="external text external">"Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application"</a>. <i>Gastroenterol Res Pract</i>. <b>2016</b>: 4105615. doi:<a href="javascript:if(confirm('https://doi.org/10.1155%2F2016%2F4105615  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1155%2F2016%2F4105615'" tppabs="https://doi.org/10.1155%2F2016%2F4105615" class="external text external">10.1155/2016/4105615</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736909  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736909'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736909" class="external text external">4736909</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26880889  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26880889'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26880889" class="external text external">26880889</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30798-3/fulltext  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30798-3/fulltext'" tppabs="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30798-3/fulltext" class="external text external">"Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial"</a>. <i>Lancet</i><span class="reference-accessdate">. Retrieved <span class="nowrap">5 February</span> 2020</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><a href="javascript:if(confirm('https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113714.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113714.htm'" tppabs="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm113714.htm" class="external text external">FDA Erbitux (cetuximab) Information Page</a></li>
<li><a href="javascript:if(confirm('http://www.erbitux.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.erbitux.com/'" tppabs="http://www.erbitux.com/" class="external text external">Erbitux site from Bristol-Myers Squibb, ImClone Systems, and Merck KGaA </a></li></ul>
<div role="navigation" class="navbox" aria-labelledby="Merck_Serono" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Merck_Serono" style="font-size:114%;margin:0 4em">Merck Serono</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Products</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Avelumab</li>
<li><a href="Bisoprolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisoprolol" title="Bisoprolol">Bisoprolol</a></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Cladribine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Cladribine'" tppabs="https://ptable.com/wiki/compounds/A/Cladribine" title="Cladribine">Cladribine</a></li>
<li>Efalizumab</li>
<li><a href="Gonadotropin_preparations.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin_preparations" title="Gonadotropin preparations">Gonadotropin preparations</a></li>
<li><a href="Human_chorionic_gonadotropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin">Human chorionic gonadotropin</a></li>
<li><a href="Interferon_beta-1a.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_beta-1a" title="Interferon beta-1a">Interferon beta-1a</a></li>
<li><a href="Levothyroxine.htm" tppabs="https://ptable.com/wiki/compounds/A/Levothyroxine" title="Levothyroxine">Levothyroxine</a></li>
<li><a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">Luteinizing hormone</a></li>
<li><a href="Metformin.htm" tppabs="https://ptable.com/wiki/compounds/A/Metformin" title="Metformin">Metformin</a></li>
<li><a href="Mitoxantrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitoxantrone" title="Mitoxantrone">Mitoxantrone</a></li>
<li>Saizen</li>
<li>Serostim</li>
<li>Tegafur/uracil</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Related</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Merck Group</li>
<li>Serono</li></ul>
</div></td></tr></tbody></table></div> 
<div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em">Targeted cancer therapy / antineoplastic agents (L01)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">CI monoclonal antibodies ("-mab")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (<a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Panitumumab)</li>
<li><i>HER2/neu</i> (Pertuzumab, <a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (+hyaluronidase)</li>
<li>Trastuzumab emtansine)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>EpCAM</i> (Catumaxomab</li>
<li>Edrecolomab)</li>
<li><i>VEGF-A</i> (Bevacizumab)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Leukemia/lymphoma</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>lymphoid: <i>CD20</i> (<a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li>
<li>Obinutuzumab</li>
<li>Ofatumumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a>), <i>CD30</i> (Brentuximab), <i>CD52</i> (<a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul>

<ul><li>myeloid: <i>CD33</i> (Gemtuzumab)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Tyrosine kinase inhibitors ("-nib")</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Receptor tyrosine kinase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>ErbB: <i>HER1/EGFR</i> (Brigatinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Olmutinib</li>
<li>Osimertinib</li>
<li>Rociletinib</li>
<li>Vandetanib)</li>
<li><i>HER1/EGFR and HER2/neu</i>
<ul><li>Afatinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li></ul></li></ul>

<ul><li>RTK class III: <i>C-kit and PDGFR</i> (Axitinib</li>
<li>Masitinib</li>
<li>Pazopanib</li>
<li>Ripretinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib)</li>
<li><i>FLT3</i> (Lestaurtinib)</li></ul>

<ul><li><i>VEGFR</i>
<ul><li>Axitinib</li>
<li>Cediranib</li>
<li>Lenvatinib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Tivozanib</li>
<li>Toceranib</li>
<li>Vandetanib</li></ul></li></ul>

<ul><li><i>ALK</i> 
<ul><li>Alectinib</li>
<li>Brigatinib</li>
<li>Ceritinib</li></ul></li></ul>

<p><i>RET inhibitors:</i> Entrectinib (ALK, ROS1, NTRK), Pemigatinib (FGFR), Selpercatinib (VEGFR, FGFR), Vandetanib (VEGFR, EGFR).
<i>c-MET inhibitors:</i> Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK)</p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Non-receptor</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>bcr-abl</i>
<ul><li>Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Nilotinib</li>
<li>Ponatinib</li>
<li>Radotinib</li></ul></li></ul>

<ul><li><i>Src</i> (Bosutinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul>

<ul><li><i>Janus kinase</i>
<ul><li>Lestaurtinib</li>
<li>Momelotinib</li>
<li>Pacritinib</li>
<li>Ruxolitinib</li></ul></li></ul>

<ul><li><i>MAP2K</i>
<ul><li>Binimetinib</li>
<li>Cobimetinib</li>
<li>Selumetinib</li>
<li>Trametinib</li></ul></li></ul>

<ul><li><i>EML4-ALK</i>
<ul><li>Crizotinib</li>
<li>Entrectinib</li>
<li>Lorlatinib</li></ul></li></ul>

<ul><li><i>Bruton's</i>
<ul><li>Acalabrutinib</li>
<li>Ibrutinib</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>fusion protein against VEGF</i> (Aflibercept)</li>
<li><i>proapoptotic peptide against ANXA2 and prohibitin</i> (Adipotide)</li>
<li><i>exotoxin against <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="Denileukin_diftitox.htm" tppabs="https://ptable.com/wiki/compounds/A/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li>
<li><i>mTOR inhibitors</i>
<ul><li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li>
<li><i>hedgehog inhibitors</i>
<ul><li>Sonidegib</li>
<li>Vismodegib</li></ul></li>
<li><i>CDK inhibitor</i> (Palbociclib</li>
<li>Ribociclib)</li>
<li>Venetoclax</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Monoclonal_antibodies_for_tumors" style="font-size:114%;margin:0 4em">Monoclonal antibodies for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;">Tumor<br></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Adecatumumab<sup>§</sup></li>
<li>Ascrinvacumab<sup>§</sup></li>
<li>Atezolizumab</li>
<li>Cixutumumab<sup>§</sup></li>
<li>Conatumumab<sup>§</sup></li>
<li>Daratumumab</li>
<li>Drozitumab<sup>§</sup></li>
<li>Duligotumab<sup>§</sup></li>
<li>Dusigitumab<sup>§</sup></li>
<li>Enfortumab vedotin<sup>†</sup></li>
<li>Enoticumab<sup>§</sup></li>
<li>Figitumumab<sup>§</sup></li>
<li>Ganitumab<sup>†</sup></li>
<li>Glembatumumab vedotin<sup>†</sup></li>
<li>Intetumumab<sup>§</sup></li>
<li>Ipilimumab</li>
<li>Iratumumab<sup>§</sup></li>
<li>Istiratumab</li>
<li>Icrucumab<sup>§</sup></li>
<li>Lexatumumab<sup>§</sup></li>
<li>Lucatumumab<sup>§</sup></li>
<li>Mapatumumab<sup>§</sup></li>
<li>Narnatumab<sup>§</sup></li>
<li>Necitumumab</li>
<li>Nesvacumab<sup>§</sup></li>
<li>Nivolumab<sup>#</sup></li>
<li>Ofatumumab</li>
<li>Olaratumab<sup>†</sup></li>
<li>Panitumumab</li>
<li>Patritumab<sup>§</sup></li>
<li>Pembrolizumab<sup>#</sup></li>
<li>Pritumumab<sup>§</sup></li>
<li>Radretumab<sup>§</sup></li>
<li>Ramucirumab</li>
<li>Rilotumumab<sup>†</sup></li>
<li>Robatumumab<sup>§</sup></li>
<li>Seribantumab<sup>§</sup></li>
<li>Tarextumab<sup>§</sup></li>
<li>Teprotumumab<sup>†</sup></li>
<li>Tovetumab<sup>§</sup></li>
<li>Vantictumab<sup>§</sup></li>
<li>Votumumab<sup>§</sup></li>
<li>Zalutumumab<sup>†</sup></li></ul>

<dl><dt><span class="nobold">"-melu-" (melanoma)</span></dt>
<dd>Flanvotumab<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Altumomab pentetate</li>
<li>Anatumomab mafenatox</li>
<li><a href="Technetium_(99mTc)_arcitumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li>
<li>Bectumomab</li>
<li>Blinatumomab</li>
<li>Detumomab</li>
<li><a href="Ibritumomab_tiuxetan.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li>
<li>Lilotomab</li>
<li>Minretumomab</li>
<li>Mitumomab</li>
<li>Moxetumomab pasudotox</li>
<li>Naptumomab estafenatox</li>
<li>Nofetumomab merpentan</li>
<li>Pemtumomab<sup>†</sup></li>
<li>Pintumomab</li>
<li>Racotumomab</li>
<li><a href="Indium_(111In)_satumomab_pendetide.htm" tppabs="https://ptable.com/wiki/compounds/A/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li>
<li>Solitomab</li>
<li>Taplitumomab paptox</li>
<li>Tenatumomab</li>
<li><a href="Tositumomab.htm" tppabs="https://ptable.com/wiki/compounds/A/Tositumomab" title="Tositumomab">Tositumomab</a></li>
<li>3F8</li></ul>

<dl><dt><span class="nobold">"-govo-" (ovarian tumor)</span></dt>
<dd>Abagovomab</dd>
<dd>Igovomab</dd>
<dd>Oregovomab</dd></dl>

<dl><dt><span class="nobold">"-pro-" (prostate tumor)</span></dt>
<dd>Capromab pendetide</dd></dl>

<dl><dt><span class="nobold">"-colo-" (colonic tumor)</span></dt>
<dd>Edrecolomab</dd>
<dd>Nacolomab tafenatox</dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Amatuximab<sup>§</sup></li>
<li>Bavituximab<sup>§</sup></li>
<li>Brentuximab vedotin</li>
<li>Carotuximab<sup>†</sup></li>
<li><a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li>Derlotuximab biotin<sup>§</sup></li>
<li>Dinutuximab</li>
<li>Ensituximab<sup>§</sup></li>
<li>Futuximab<sup>§</sup></li>
<li>Girentuximab<sup>†</sup></li>
<li>Indatuximab ravtansine<sup>§</sup></li>
<li>Isatuximab</li>
<li>Loncastuximab tesirine</li>
<li>Margetuximab<sup>†</sup></li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li>
<li>Siltuximab</li>
<li>Ublituximab<sup>†</sup></li>
<li>IMAB362</li></ul>

<p>"-mexi-" (melanoma): Ecromeximab<sup>§</sup></p>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abituzumab<sup>§</sup></li>
<li><a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li>
<li>Belantamab mafodotin</li>
<li>Bevacizumab</li>
<li>Bivatuzumab mertansine<sup>§</sup></li>
<li>Brontictuzumab<sup>§</sup></li>
<li>Cantuzumab mertansine<sup>§</sup></li>
<li>Cantuzumab ravtansine<sup>§</sup></li>
<li>Cirmtuzumab</li>
<li>Citatuzumab bogatox<sup>§</sup></li>
<li>Clivatuzumab tetraxetan</li>
<li>Cofetuzumab pelidotin</li>
<li>Dacetuzumab<sup>§</sup></li>
<li>Demcizumab<sup>§</sup></li>
<li>Dalotuzumab<sup>§</sup></li>
<li>Denintuzumab mafodotin<sup>§</sup></li>
<li>Elotuzumab</li>
<li>Emactuzumab<sup>§</sup></li>
<li>Emibetuzumab<sup>§</sup></li>
<li>Enoblituzumab<sup>§</sup></li>
<li>Etaracizumab<sup>§</sup></li>
<li>Farletuzumab<sup>§</sup></li>
<li>Ficlatuzumab<sup>§</sup></li>
<li>Flotetuzumab<sup>§</sup></li>
<li>Gemtuzumab ozogamicin</li>
<li>Imgatuzumab<sup>§</sup></li>
<li>Inotuzumab ozogamicin<sup>†</sup></li>
<li>Labetuzumab<sup>§</sup></li>
<li>Lifastuzumab vedotin<sup>§</sup></li>
<li>Lintuzumab<sup>§</sup></li>
<li>Lorvotuzumab mertansine<sup>§</sup></li>
<li>Lumretuzumab<sup>§</sup></li>
<li>Matuzumab<sup>§</sup></li>
<li>Milatuzumab<sup>§</sup></li>
<li>Nimotuzumab<sup>†</sup></li>
<li>Obinutuzumab</li>
<li>Ocaratuzumab<sup>§</sup></li>
<li>Otlertuzumab<sup>§</sup></li>
<li>Onartuzumab<sup>§</sup></li>
<li>Oportuzumab monatox<sup>†</sup></li>
<li>Parsatuzumab<sup>§</sup></li>
<li>Pertuzumab</li>
<li>Pinatuzumab vedotin<sup>§</sup></li>
<li>Polatuzumab vedotin<sup>†</sup></li>
<li>Rosmantuzumab</li>
<li>Rovalpituzumab tesirine<sup>†</sup></li>
<li>Sacituzumab govitecan</li>
<li>Sibrotuzumab<sup>§</sup></li>
<li>Simtuzumab<sup>§</sup></li>
<li>Tacatuzumab tetraxetan<sup>§</sup></li>
<li>Tigatuzumab<sup>§</sup></li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup></li>
<li>Tucotuzumab celmoleukin<sup>§</sup></li>
<li>Vandortuzumab vedotin<sup>§</sup></li>
<li>Vanucizumab<sup>§</sup></li>
<li>Veltuzumab<sup>§</sup></li>
<li>Vorsetuzumab mafodotin<sup>§</sup></li>
<li>CBR96-doxorubicin immunoconjugate</li>
<li>PankoMab</li></ul>

<dl><dt><span class="nobold">"-gozu-" (ovarian tumor)</span></dt>
<dd>Sofituzumab vedotin<sup>§</sup></dd></dl>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Rat/mouse hybrid<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Catumaxomab</li>
<li>Ertumaxomab<sup>§</sup></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized<br></th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Depatuxizumab mafodotin<sup>†</sup></li>
<li>Duvortuxizumab</li>
<li>Ontuxizumab<sup>§</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Growth_factor_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Growth_factor_receptor_modulators" style="font-size:114%;margin:0 4em">Growth factor receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Angiopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Angiopoietin 1</li>
<li>Angiopoietin 4</li></ul>

<ul><li><i>Antagonists:</i> Angiopoietin 2</li>
<li><span class="new">Angiopoietin 3</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">CE-245677</span></li>
<li>Rebastinib</li></ul>

<ul><li><i>Antibodies:</i> Evinacumab (against angiopoietin 3)</li>
<li>Nesvacumab (against angiopoietin 2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CNTF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Axokine</li>
<li>CNTF</li>
<li><span class="new">Dapiclermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF (ErbB)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">EGF<br><small>(ErbB1/HER1)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Amphiregulin</li>
<li>Betacellulin</li>
<li>EGF (urogastrone)</li>
<li>Epigen</li>
<li>Epiregulin</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Murodermin</li>
<li>Nepidermin</li>
<li>Transforming growth factor alpha (TGFα)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><span class="new">Agerafenib</span></li>
<li>Brigatinib</li>
<li>Canertinib</li>
<li>Dacomitinib</li>
<li><a href="Erlotinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Erlotinib" title="Erlotinib">Erlotinib</a></li>
<li><a href="Gefitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Gefitinib" title="Gefitinib">Gefitinib</a></li>
<li>Grandinin</li>
<li>Icotinib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Neratinib</li>
<li>Osimertinib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> <a href="Cetuximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetuximab" title="Cetuximab">Cetuximab</a></li>
<li><span class="new">Depatuxizumab</span></li>
<li>Depatuxizumab mafodotin</li>
<li>Futuximab</li>
<li>Imgatuzumab</li>
<li>Matuzumab</li>
<li>Necitumumab</li>
<li>Nimotuzumab</li>
<li>Panitumumab</li>
<li>Zalutumumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB2/HER2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: <i>Unknown/none</i></li></ul>

<ul><li><i>Antibodies:</i> Ertumaxomab</li>
<li>Pertuzumab</li>
<li><a href="Trastuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Trastuzumab" title="Trastuzumab">Trastuzumab</a></li>
<li><span class="new">Trastuzumab duocarmazine</span></li>
<li>Trastuzumab emtansine</li></ul>

<ul><li><i>Kinase inhibitors:</i> Afatinib</li>
<li><span class="new">AG-490</span></li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Mubritinib</li>
<li>Neratinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB3/HER3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neuregulins (heregulins) (1, 2, 6 (neuroglycan C))</li></ul>

<ul><li><i>Antibodies:</i> Duligotumab</li>
<li>Patritumab</li>
<li>Seribantumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">ErbB4/HER4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Betacellulin</li>
<li>Epigen</li>
<li>Heparin-binding EGF-like growth factor (HB-EGF)</li>
<li>Neuregulins (heregulins) (1, 2, 3, 4, <span class="new">5 (tomoregulin, TMEFF)</span>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)</li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Trafermin</li>
<li><span class="new">Velafermin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22)</li>
<li><a href="Palifermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Palifermin" title="Palifermin">Palifermin</a></li>
<li><span class="new">Repifermin</span></li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> <span class="new">Aprutumab</span></li>
<li><span class="new">Aprutumab ixadotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR3</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 8, 9, 18, 23)</li>
<li>Selpercatinib</li>
<li>Sprifermin</li>
<li>Trafermin</li></ul>

<ul><li><i>Antibodies:</i> Burosumab (against FGF23)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">FGFR4</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ersofermin</span></li>
<li>FGF (1, 2 (bFGF), 4, 6, 8, 9, 19)</li>
<li>Trafermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> FGF15/19</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">HGF (c-Met)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Hepatocyte growth factor</li></ul>

<ul><li><i>Potentiators:</i> Dihexa (PNB-0408)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AM7</span></li>
<li><span class="new">AMG-458</span></li>
<li><span class="new">Amuvatinib</span></li>
<li><span class="new">BMS-777607</span></li>
<li>Cabozantinib</li>
<li>Crizotinib</li>
<li>Foretinib</li>
<li><span class="new">Golvatinib</span></li>
<li><span class="new">INCB28060</span></li>
<li><span class="new">JNJ-38877605</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li><span class="new">MK-2461</span></li>
<li><span class="new">PF-04217903</span></li>
<li><span class="new">PF-2341066</span></li>
<li><span class="new">PHA-665752</span></li>
<li><span class="new">SU-11274</span></li>
<li>Tivantinib</li>
<li>Volitinib</li></ul>

<ul><li><i>Antibodies:</i> Emibetuzumab</li>
<li>Ficlatuzumab</li>
<li>Flanvotumab</li>
<li>Onartuzumab</li>
<li>Rilotumumab</li>
<li><span class="new">Telisotuzumab</span></li>
<li><span class="new">Telisotuzumab vedotin</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: des(1-3)IGF-1</li>
<li>Insulin-like growth factor-1 (somatomedin C)</li>
<li>IGF-1 LR3</li>
<li>Insulin-like growth factor-2 (somatomedin A)</li>
<li><a href="Insulin.htm" tppabs="https://ptable.com/wiki/compounds/A/Insulin" title="Insulin">Insulin</a></li>
<li><a href="Mecasermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Mecasermin" title="Mecasermin">Mecasermin</a></li>
<li>Mecasermin rinfabate</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">BMS-754807</span></li>
<li>Linsitinib</li>
<li><span class="new">NVP-ADW742</span></li>
<li><span class="new">NVP-AEW541</span></li>
<li><span class="new">OSl-906</span></li></ul>

<ul><li><i>Antibodies:</i> <span class="new">AVE-1642</span></li>
<li>Cixutumumab</li>
<li>Dalotuzumab</li>
<li>Figitumumab</li>
<li>Ganitumab</li>
<li>Robatumumab</li>
<li><span class="new">R1507</span></li>
<li>Teprotumumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IGF-2</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists</i>: Insulin-like growth factor-2 (somatomedin A)</li></ul>

<ul><li><i>Antibodies:</i> Dusigitumab</li>
<li><span class="new">Xentuzumab</span> (against IGF-1 and IGF-2)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Binding proteins:</i> IGFBP (1, 2, 3, 4, 5, 6, 7)</li></ul>

<ul><li><i>Cleavage products/derivatives with unknown target:</i> <span class="new">Glypromate (GPE, (1-3)IGF-1)</span></li>
<li>Trofinetide</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">LNGF (p75<sup>NTR</sup>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BDNF</li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li>NGF</li>
<li>NT-3</li>
<li>NT-4</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li><span class="new">EVT-901 (SAR-127963)</span></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Antibodies:</i> <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">LEVI-04 (p75<sup>NTR</sup>-Fc)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">PDGF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Becaplermin.htm" tppabs="https://ptable.com/wiki/compounds/A/Becaplermin" title="Becaplermin">Becaplermin</a></li>
<li>Platelet-derived growth factor (A, B, C, D)</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li>Crenolanib</li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Lenvatinib</li>
<li>Masitinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Radotinib</li>
<li>Quizartinib</li>
<li>Ripretinib</li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li>Toceranib</li></ul>

<ul><li><i>Antibodies:</i> Olaratumab</li>
<li>Ramucirumab</li>
<li>Tovetumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">RET (GFL)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Glial cell line-derived neurotrophic factor (GDNF)</li>
<li><span class="new">Liatermin</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Neurturin (NRTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Artemin (ARTN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GFRα4</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Persephin (PSPN)</li></ul>

<ul><li><i>Kinase inhibitors:</i> Vandetanib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Ancestim</li>
<li>Stem cell factor</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li>Axitinib</li>
<li><a href="Dasatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Dasatinib" title="Dasatinib">Dasatinib</a></li>
<li><a href="Imatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Imatinib" title="Imatinib">Imatinib</a></li>
<li>Masitinib</li>
<li>Nilotinib</li>
<li>Pazopanib</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Trk</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkA</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BNN-20</li>
<li>BNN-27</li>
<li>Cenegermin</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA-S</a></li>
<li><span class="new">Gambogic amide</span></li>
<li>NGF</li>
<li>Tavilermide</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">ALE-0540</span></li>
<li><a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">Dexamethasone</a></li>
<li>FX007</li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>

<ul><li><i>Negative allosteric modulators:</i> <span class="new">VM-902A</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">Milciclib</span></li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li>
<li>Rebastinib</li>
<li><span class="new">SNA-120 (pegylated K252a)</span>)</li></ul>

<ul><li><i>Antibodies:</i> <i>Against TrkA:</i> <span class="new">GBR-900</span>; <i>Against NGF:</i> <span class="new">ABT-110 (PG110)</span></li>
<li><span class="new">ASP-6294</span></li>
<li>Fasinumab</li>
<li><span class="new">Frunevetmab</span></li>
<li>Fulranumab</li>
<li><span class="new">MEDI-578</span></li>
<li><span class="new">Ranevetmab</span></li>
<li>Tanezumab</li></ul>

<ul><li><i>Aptamers:</i> <i>Against NGF:</i> <span class="new">RBM-004</span></li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">ReN-1820 (TrkAd5)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkB</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">3,7-DHF</span></li>
<li><span class="new">3,7,8,2'-THF</span></li>
<li>4'-DMA-7,8-DHF</li>
<li><span class="new">7,3'-DHF</span></li>
<li>7,8-DHF</li>
<li><span class="new">7,8,2'-THF</span></li>
<li>7,8,3'-THF</li>
<li><a href="Amitriptyline.htm" tppabs="https://ptable.com/wiki/compounds/A/Amitriptyline" title="Amitriptyline">Amitriptyline</a></li>
<li>BDNF</li>
<li>BNN-20</li>
<li>Deoxygedunin</li>
<li><a href="Selegiline.htm" tppabs="https://ptable.com/wiki/compounds/A/Deprenyl" title="Deprenyl" class="mw-redirect">Deprenyl</a></li>
<li>Diosmetin</li>
<li><span class="new">DMAQ-B1</span></li>
<li>HIOC</li>
<li>LM22A-4</li>
<li><a href="N-Acetylserotonin.htm" tppabs="https://ptable.com/wiki/compounds/A/N-Acetylserotonin" title="N-Acetylserotonin">N-Acetylserotonin</a></li>
<li>NT-3</li>
<li>NT-4</li>
<li>Norwogonin (5,7,8-THF)</li>
<li>R7</li>
<li>R13</li>
<li><span class="new">TDP6</span></li></ul>

<ul><li><i>Antagonists:</i> ANA-12</li>
<li>Cyclotraxin B</li>
<li>Gossypetin (3,5,7,8,3',4'-HHF)</li></ul>

<ul><li><i>Ligands:</i> <a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TrkC</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> BNN-20</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA</a></li>
<li>NT-3</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Altiratinib</span></li>
<li><span class="new">AZD-6918</span></li>
<li><span class="new">CE-245677</span></li>
<li><span class="new">CH-7057288</span></li>
<li><span class="new">DS-6051</span></li>
<li>Entrectinib</li>
<li><span class="new">GZ-389988</span></li>
<li><a href="K252a.htm" tppabs="https://ptable.com/wiki/compounds/A/K252a" title="K252a">K252a</a></li>
<li>Larotrectinib</li>
<li>Lestaurtinib</li>
<li><span class="new">ONO-4474</span></li>
<li><span class="new">ONO-5390556</span></li>
<li><span class="new">PLX-7486</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">VEGF</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Placental growth factor (PGF)</li>
<li>Ripretinib</li>
<li><span class="new">Telbermin</span></li>
<li>VEGF (A, B, C, D (FIGF))</li></ul>

<ul><li><i>Allosteric modulators:</i> Cyclotraxin B</li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li>
<li><span class="new">Altiratinib</span></li>
<li>Axitinib</li>
<li>Cabozantinib</li>
<li>Cediranib</li>
<li><a href="Lapatinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Lapatinib" title="Lapatinib">Lapatinib</a></li>
<li>Lenvatinib</li>
<li>Motesanib</li>
<li>Nintedanib</li>
<li>Pazopanib</li>
<li>Pegaptanib</li>
<li>Rebastinib</li>
<li>Regorafenib</li>
<li>Semaxanib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li>
<li>Toceranib</li>
<li>Tivozanib</li>
<li>Vandetanib</li>
<li><span class="new">WHI-P 154</span></li></ul>

<ul><li><i>Antibodies:</i> Alacizumab pegol</li>
<li>Bevacizumab</li>
<li>Icrucumab</li>
<li>Ramucirumab</li>
<li><a href="Ranibizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Ranibizumab" title="Ranibizumab">Ranibizumab</a></li></ul>

<ul><li><i>Decoy receptors:</i> Aflibercept</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional growth factors:</i> Adrenomedullin</li>
<li>Colony-stimulating factors (see here instead)</li>
<li>Connective tissue growth factor (CTGF)</li>
<li>Ephrins (A1, A2, A3, A4, A5, B1, B2, B3)</li>
<li>Erythropoietin (see here instead)</li>
<li>Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)</li>
<li>Glia maturation factor (GMF)</li>
<li>Hepatoma-derived growth factor (HDGF)</li>
<li>Interleukins/T-cell growth factors (see here instead)</li>
<li>Leukemia inhibitory factor (LIF)</li>
<li>Macrophage-stimulating protein (MSP; HLP, HGFLP)</li>
<li>Midkine (NEGF2)</li>
<li>Migration-stimulating factor (MSF; PRG4)</li>
<li>Oncomodulin</li>
<li>Pituitary adenylate cyclase-activating peptide (PACAP)</li>
<li>Pleiotrophin</li>
<li>Renalase</li>
<li>Thrombopoietin (see here instead)</li>
<li>Wnt signaling proteins</li></ul>

<ul><li><i>Additional growth factor receptor modulators:</i> Cerebrolysin (neurotrophin mixture)</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Cytokine receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>




<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-07-17" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Cetuximab&oldid=968063177  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Cetuximab&oldid=968063177'" tppabs="https://en.wikipedia.org/wiki/?title=Cetuximab&oldid=968063177">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>